Bottom line
MASMX vs VB: the short answer
MASMX (Madison Small Cap Fund) and VB (Vanguard Small-Cap Index Fund) are both mutual funds.
But VB is far broader, holding 1,317 positions to 52 for MASMX, so beyond the top names it adds exposure MASMX doesn't have.
VB is cheaper at 0.03% vs 1.35% — a difference of $132 a year per $10,000 invested.
Over five years, VB returned +7.4% a year vs +2.2% for MASMX.
MASMX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
MASMX vs VB side by side
| MASMX | VB | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Madison | Vanguard |
| Category | Small-Cap | Small-Cap |
| Expense ratio | 1.35% | 0.03% |
| Annual cost per $10k | $135 | $3 |
| 10-yr cost on $10k (prospectus) | $2,015 | $39 |
| Max front load | 5.75% | None |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | −12.6% | +8.9% |
| 5-yr return (annualized) | +2.2% | +7.4% |
| 10-yr return (annualized) | — | +10.4% |
| Best quarter | — | +27.1% |
| Worst quarter | — | −30.1% |
| Net assets (fund) | $154.9M | $188.7B |
| Number of holdings | 52 | 1,317 |
| Portfolio turnover | 35% | 17% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
MASMX and VB share none of their top holdings.
MASMX top 10
- State Street Global Advisors — 5.53%
- Encompass Health Corp — 4.52%
- Scotts Miracle-Gro Co/The — 3.84%
- Knowles Corp — 3.33%
- HealthEquity Inc — 3.15%
- Workiva Inc — 3.01%
- Hayward Holdings Inc — 2.92%
- Core & Main Inc — 2.83%
- Carlisle Cos Inc — 2.72%
- Gitlab Inc — 2.55%
VB top 10
- Vanguard Cmt Funds-Vanguard Market Liquidity Fund — 1.50%
- Credo Technology Group Holding Ltd — 0.55%
- Jabil Inc — 0.49%
- REVOLUTION Medicines Inc — 0.46%
- Astera Labs Inc — 0.45%
- Natera Inc — 0.45%
- EMCOR Group Inc — 0.45%
- Twilio Inc — 0.38%
- NRG Energy Inc — 0.37%
- MKS Instruments Inc — 0.37%
FAQ
What is the difference between MASMX and VB?
Which is cheaper, MASMX or VB?
Should I own both MASMX and VB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.